Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study (Q34473925)

2 August 2017

Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study (English)

1 reference

2 August 2017

Newman-Tancredi A

1

1 reference

2 August 2017

Gavaudan S

2

1 reference

2 August 2017

Conte C

3

1 reference

2 August 2017

Chaput C

4

1 reference

2 August 2017

Touzard M

5

1 reference

2 August 2017

Verrièle L

6

1 reference

2 August 2017

Audinot V

7

1 reference

2 August 2017

Millan MJ

8

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 August 1998

1 reference

European Journal of Pharmacology

2 August 2017

1 reference

2 August 2017

355

1 reference

2 August 2017

2-3

1 reference

2 August 2017

245-256

1 reference

Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

The 5-HT1A receptor antagonist (S)-UH-301 blocks the qR)-8-OH-DPAT-induced inhibition of serotonergic dorsal raphe cell firing in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

5-HT1A receptors are not involved in clozapine's lack of cataleptogenic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Molecular biology of 5-HT receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Serotonin receptors in cognitive behaviors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

[3H]WAYâ 100635 for 5â HT1A receptor autoradiography in human brain: a comparison with [3H]8â OHâ DPAT and demonstration of increased binding in the frontal cortex in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Evaluation of Butaclamol in Chronic Schizophrenic Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Effects of atypical antipsychotic agents on social behavior in rodents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Electrophysiological evidence for a large receptor reserve for inhibition of dorsal raphe neuronal firing by 5-HT1A agonists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

5-HT1A receptor agonists: recent developments and controversial issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Dual couplings of the cloned 5-HT1A receptor to both adenylyl cyclase and phospholipase C is mediated via the same Gi protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

BMY 14802, a sigma receptor ligand for the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

NAN-190: an arylpiperazine analog that antagonizes the stimulus effects of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

The putative 5-HT1A receptor antagonists NAN-190 and BMY 7378 are partial agonists in the rat dorsal raphe nucleus in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Diversity and selectivity of receptor-G protein interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Augmentation with buspirone: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

[3H]8-OH-DPAT labels a 5-HT site coupled to inhibition of phosphoinositide hydrolysis in the dorsal raphe.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Clozapine inhibits serotoninergic transmission by an action at alpha 1-adrenoceptors not at 5-HT1A receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

S 15535: a highly selective benzodioxopiperazine 5-HT1A receptor ligand which acts as an agonist and an antagonist at presynaptic and postsynaptic sites respectively

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Further evidence for differential affinity states of the serotonin1A receptor in rat hippocampus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

S 15535 and WAY 100,635 antagonise 5-HT-stimulated [35S]GTP gamma S binding at cloned human 5-HT1A receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Activity of serotonin (5-HT) receptor agonists, partial agonists and antagonists at cloned human 5-HT1A receptors that are negatively coupled to adenylate cyclase in permanently transfected HeLa cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Functional expression of human 5-HT1A receptors and differential coupling to second messengers in CHO cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Cell-specific physical and functional coupling of human 5-HT1A receptors to inhibitory G protein alpha-subunits and lack of coupling to Gs alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

The potent activity of the 5-HT1A receptor agonists, S 14506 and S 14671, in the rat forced swim test is blocked by novel 5-HT1A receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

A Clinical Guide to Antipsychotic Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Use of buspirone in the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Characterisation of a cloned human 5-HT1A receptor cell line using [35S]GTP gamma S binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Characterization of recombinant human serotonin 5HT1A receptors expressed in Chinese hamster ovary cells. [3H]spiperone discriminates between the G-protein-coupled and -uncoupled forms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Pharmacological characterisation of [35S]-GTPgammaS binding to Chinese hamster ovary cell membranes stably expressing cloned human 5-HT1D receptor subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900483-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0014-2999(98)00483-X

1 reference

2 August 2017

1 reference